Matthew Meyerson joins Isabl as Chairman of the Scientific Advisory Board
--
Isabl is pleased to announce that Matthew Meyerson, MD, PhD has joined the company as the Chair of the Scientific Advisory Board. Dr. Meyerson is an internationally recognized thought leader in the field of cancer genomics and was co-founder of Foundation Medicine. He is currently the Director of the Center for Cancer Genomics at Dana-Farber Cancer Institute, and Professor of Genetics and Medicine at Harvard Medical School.
Dr. Meyerson’s research has used genomics to discover the causes of and identify potential therapeutic approaches for cancer. His laboratory has made seminal discoveries of cancer-causing mutations in a variety of cancer types, and has identified potential therapeutic opportunities and mechanisms of resistance relevant to cancer treatment. Dr. Meyerson has also helped lead large national cancer genomic efforts, including The Cancer Genome Atlas project (TCGA). Dr. Meyerson has received many awards in recognition of his accomplishments in cancer genomics, such as election to the National Academy of Medicine and being named the second most influential scientist across all scientific fields by Thomson Reuters.
“Clinical cancer genomics has made great strides using targeted panels, but we are still missing what happens in 99% of the genome. Moving to whole genome and whole transcriptome sequencing will allow us to find all the key alterations in cancer genomes and help us identify more opportunities for patient tailored therapy,” said Dr. Meyerson.
“We are pleased to have Dr. Meyerson’s leadership on our SAB, and his partnership toward our shared vision of bringing complete genomic characterization to the clinic,” said Dr. Elli Papaemmanuil, CEO of Isabl. “Matthew understands the unmet clinical need, how cancer whole genome and transcriptome analysis uniquely fulfills the promise of patient tailored medicine and what it takes to bring a state of the art research assay into standard of care.”
